So far the data, with a Car-T Legend licensed to Novartis, lag antibody approaches.

But results come from a curated dataset, with no in-trial comparator.

Global data are in the same ballpark as Chinese results presented earlier this year.

A common mutation comes into play for PRMT5 inhibition.

Investors now have more reasons to doubt Harmoni's ability to back US approval.

Tolerability could decide first-line therapy in EGFRm disease.

Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.

The EGFR x HER3 ADC iza-bren looks good, but still has much to prove.

Posters and mini-orals include another VEGF bispecific.

Summit and Nuvalent have scored prized plenary spots.